Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-636-9 | CAS number: 108-99-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- repeated dose toxicity: oral
- Remarks:
- combined repeated dose and carcinogenicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 15 November 2004-17 November 2006
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Chronic combined oral toxicity/carcinogenicity study conducted according to guidelines by the U.S. National Toxicology Program
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: Specifications for the Conduct of Studies to Evaluate the Toxic and Carcinogenic Potential of Chemical, Biological, and Physical Agents in Laboratory Animals for the National Toxicology Program (NTP) October 2006
- Principles of method if other than guideline:
- The guideline "Specifications for the Conduct of Studies to Evaluate the Toxic and Carcinogenic Potential of Chemical, Biological, and Physical Agents in Laboratory Animals for the National Toxicology Program (NTP), October 2006" is similar to the OECD Combined Toxicity/Carcinogenicity Guideline 453.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 3-methylpyridine
- EC Number:
- 203-636-9
- EC Name:
- 3-methylpyridine
- Cas Number:
- 108-99-6
- Molecular formula:
- C6H7N
- IUPAC Name:
- 3-methylpyridine
- Test material form:
- other: liquid
- Details on test material:
- - Name of test material (as cited in study report): beta-picoline
- Physical state: clear liquid
- Analytical purity: >96% by Karl Fischer water analysis, functional group titration and gas chromatography
- Impurities (identity and concentrations):
- Composition of test material, percentage of components: 0.01 mg/ml in deionized water
- Isomers composition:
- Purity test date: > 96%
- Lot/batch No.:11108C1 from Aldrich Chemical Company
- Stability under test conditions:Stability of 0.01 mg/ml formulations was confirmed for at least 3 weeks when stored in amber bottles at room temperature.
- Storage condition of test material: stored in the dark at 1-8 degrees C.
- Other:
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms, Germantown, NY, USA
- Age at study initiation: 6 weeks
- Fasting period before study: not applicable
- Housing: Cages were polycarbonate and racks were rotated every two weeks during the study. Bedding: irradiated Sani-Chips (P.J. Murphy Forest Products Corp., Montville, NJ), changed weekly
- Diet: irradiated NTP-2000 wafer feed (Zeigler Brothers, Inc., Gardners, PA), available ad libitum
- Water (e.g. ad libitum): tap water via glass water bottles with stainless steel sipper tubes, available ad libitum, changed at least twice per week
- Acclimation period: up to 12 days.
- Method of kill: carbon dioxide asphyxiation
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.2 ± 3
- Humidity (%): 50% ± 15%
- Air changes (per hr): 10/hour
- Photoperiod (hrs dark / hrs light): 12 /12
IN-LIFE DATES: From: 15 November 2004. To: 17 February 2006.
Administration / exposure
- Route of administration:
- oral: drinking water
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Dosing solutions were prepared five times for the 2-year studies by mixing the test material with tap water. The pH was adjusted if necessary with acetic acid to bring it to 6-7.5 pH units. Stability studies of 10 µl/ml formulations were performed periodically by HPLC with ultraviolet light detection and found to be stable (± 10%) under the animal room conditions. They were made and stored in sealed polyethylene bottles. The water was administered to animals in glass bottles with stainless steel sipper tubes and Teflon® seals. Analytical data indicate that little or no volatization occurred under these conditions.
- Duration of treatment / exposure:
- 104-105 weeks
- Frequency of treatment:
- daily, in drinking water, available ad libitum.
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
156.25 mg/L
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
312.5 mg/L
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
625 mg/L
Basis:
actual ingested
- No. of animals per sex per dose:
- 50 per sex per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Groups of 50 male and 50 female F344 rats were given drinking water containing 0, 156.25, 312.5 or 625 mg/L 3-methylpyridine for 104 weeks.
All animals were observed twice daily. Clinical findings were recorded weekly, and body weights were recorded at the start of the study and weekly. Haematology and clinical chemistry values were measured in animals of the week 14 section of the study. A complete necropsy and microscopic examination were performed. All major tissues were fixed and preserved in 10% neutral buffered formalin, processed, sectioned, and stained with hematoxylin and eosin for microscopic examination. Necropsy was performed on all core (main) study animals. Organs weighed were heart, right kidney, liver, lung, right testis, and thymus. Complete histopathology were completed on the 0 and 625 mg/L dose groups. The following tissues were examined: adrenal gland, bone (with marrow), brain, clitoral gland, esophagus, heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, liver, lung, lymph nodes (mandibular and mesenteric), mammary gland (with adjacent skin), nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, stomach, testis (with epididymis and seminal vesicle), thymus, thyroid gland, trachea, urinary bladder, uterus. Gross lesions and tissue masses were recorded and analyzed. The kidney of male rats and the liver of all rats were also examined in all other exposure groups. Hematology: hematocrit; hemoglobin concentration; erythrocyte, reticulocyte, nucleated erythrocyte, and platelet counts; mean cell volume; mean cell hemoglobin; mean cell hemoglobin concentration; and leukocyte count and differentials. Clinical chemistry: urea nitrogen, creatinine, protein, albumin, alanine aminotransferase, alkaline phosphatase, creatine kinase, sorbital dehyrodrogenase, bile acids. - Positive control:
- none
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Clinical findings were recorded weekly for the first 4 weeks then monthlyafterwards.
BODY WEIGHT: Yes
- Time schedule for examinations: Body weights were recorded at the start of the study, weekly for the first 3 months,
and then monthly until study termination.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: Water consumption was measured weekly by cage for the first 3 months and every 4 weeks thereafter. Rats were housed 2-3 per cage.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: A necropsy was performed on all animals, in which organs and tissues were examined for grossly visible lesions and all major tissues were observed microscopically. The following tissues were examined: adrenal gland, bone (with marrow), brain, clitoral gland, esophagus, heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, liver, lung, lymph nodes (mandibular and mesenteric), mammary gland (with adjacent skin), nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, stomach, testis (with epididymis and seminal vesicle), thymus, thyroid gland, trachea, urinary bladder, uterus and gross lesions and tissue masses. - Statistics:
- The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958), or Cox’s method (1972) for testing two groups for equality. Tarone’s life table test (1975) was used to identify dose-related trends. All reported P values for the survival analysis were two sided.
Survival-adjusted neoplasm rates for each group and each site-specific neoplasm are given. The survival-adjusted Poly-k test (Bailer and Portier, 1988; Portier and Bailer, 1989; Piegorsch and Bailer, 1997) was used to assess neoplasm and nonneoplastic lesion prevalence, with k= 3 as recommended by Bailer and Portier, 1988. Tests of significance included pairwise comparisons of each dosed group with controls and a test for an overall dose-related trend. Continuity-corrected Poly-3 tests were used in the analysis of lesion incidence, and reported P values are 1-sided. The significant of lower incidences or decreasing trends in lesions is represented as 1-P with a post-script “N”.
For continuous variables, organ and body weight data were analyzed with the parametric multiple comparison procedures of Dunnett (1955) and Williams (1971, 1972). For skewed distribution values (clinical chemistry, etc.), nonparametric multiple comparison methods were used to assess the significance of the dose-related trends.
Historical control values for a given route of administration were used to assist in interpretation of control and experimental values. The relevant historical control database includes studies undertaken after 2000 when a modified diet was adopted.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Final mean body weights and body weight gains of rats (male and female) exposed to 625 mg/L were slightly less (9-10%) than those of the controls.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- Water consumption by male and female rats exposed to 625 mg/L was less than that by controls due to poor palatability.
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Chronic progressive nephropathy in males was increased in 625 mg/L groups. Squamous cell tumours were observed in the oral cavity.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Alveolar epithelium hyperplasia (increased Type II pneumocytes without cellular atypia) and squamous metaplasia (noncuboid epithelia) were increased, but not significantly, in all exposed groups of females compared to those of controls.
- Histopathological findings: neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- See Carcinogenicity Section 7.7.1
- Details on results:
- There was no effect of chronic exposure to 3-methylpyridine on mortality or clinical toxicity. Decreased water consumption was evident in 625 mg/L males and females compared to controls throughout the study. Body weights were slightly decreased in high dose males (10%) and females (9%)compared to controls. There was some evidence of lung tumours in female rats. Incidences of alveolar/bronchiolar adenoma in high dose females were significantly greater than those in concurrent controls, and slightly higher than in historical controls. Lung tumours (alveolar/bronchiolar adenoma and/or carcinoma) were observed in female rats at a rate slightly above the historical control levels, with a statistically significant trend test.
Alveolar epithelial hyperplasia and metaplasion, and squamous cell papilloma or carcinoma (combined) in the oral cavity were observed (1-2 per 50 animals). But due to the low incidences, the lesions are not considered to be related to the treatment.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 312.5 mg/L drinking water
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: equivalent to 12 mg/k bw/day in males and 14 mg/kg bw/d in females.
- Dose descriptor:
- LOAEL
- Effect level:
- 625 mg/L drinking water
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: equivalent to 22 mg/kg bw/d in males and26 mg/kg bw/d in females. This dose resulted in body and liver weight changes, water consumption decreases, and nephropathy in males.
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
A category of pyridine and methyl pyridine derivatives is comprised of: pyridine, 2-methylpyridine, 3-methylpyridine and 4-methylpyridine. The basis of the category is structural similarity (based on the pyridine unsaturated ring structure) and similar physical properties, environmental fate and ecotoxicity, and mammalian toxicity. Similar toxicological properties derive from similar physical-chemical properties and common pathways of metabolism and elimination among all members of the category. This category is accepted by the U.S. Environmental Protection Agency (EPA).
Applicant's summary and conclusion
- Conclusions:
- A chronic toxicity/carcinogenicity study (2-year) in F344 rats was undertaken with 3-methypyridine at doses of 156.25, 312.5 and 625 mg/L in the drinking water (6-7, 12-14, and 38 mg/kg bw/d, respectively in males and females) and a draft report is available for review.. There were no substance-related effects on survival or clinical findings. Body weight changes were similar in exposed animals and control animals. Consumption of water in males and females was decreased at the highest dose, with evidence of dehydration. A dose of 625 mg/L resulted in an increase in alveolar/bronchiolar adenomas and adenomas/carcinomas (combined) in female rats. The NOAEL is estimated to be 312.5 mg/L or 12-14 mg/kg bw/d.
Three members of the pyridine and methyl pyridine derivatives category are listed in Regulation (EC) No. 1272/2008, Annex VI: Pyridine (Index #613-002-00-7, 2-methylpyridine (Index # 613-036-00-2) and 4-methylpyridine (Index # 613-037-00-8). The classifications are similar within the category, with the methyl derivatives classified as more corrosive than pyridine. The application of a chemical category is adequate for classification and labelling.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.